)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Formycon (FYB) investor relations material
Formycon H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary13 Aug, 2025
Executive summary
Achieved key operational and regulatory milestones in H1 2025, including product launches, approvals in multiple regions, and a phase three waiver for a biosimilar, accelerating development and reducing costs.
Transitioned into a commercial company with two products on major global markets, focusing on pipeline execution, commercial growth, and maximizing asset value.
Strategic focus on biosimilars, innovation, and geographic diversification to drive sustainable profitability by 2026.
Issued a €70 million bond, significantly oversubscribed, strengthening liquidity for future growth.
Faced challenging US biosimilar market with slower-than-expected penetration and deeper price discounts, impacting revenue.
Financial highlights
H1 2025 revenue was €9.0 million, down from €26.9 million in H1 2024, mainly due to lower milestone, royalty, and deferred revenue, as well as US market challenges.
EBITDA for H1 2025 was €-17.9 million, compared to €-16.9 million in H1 2024; adjusted EBITDA was €-19.2 million (H1 2024: €-2.1 million), reflecting negative equity income from Bioeq AG.
Operational cost of sales for H1 2025 was €22.4 million, down from €25.0 million in H1 2024.
Cash and cash equivalents stood at €27.3 million as of June 30, 2025, excluding bond proceeds.
Equity ratio at 55.0% as of June 30, 2025.
Outlook and guidance
Full-year 2025 revenue expected between €55.0 million and €65.0 million, with most sales contributions anticipated in Q4.
EBITDA and adjusted EBITDA for 2025 forecasted between €-20.0 million and €-10.0 million.
Major revenue drivers in H2: upfront payments from licensing deals and increased royalties from key products.
Positive EBITDA targeted for 2026 or 2027, driven by product launches and pipeline progress.
Working capital guidance raised to €55.0–65.0 million, supported by bond proceeds.
What's the plan for FYB201 in the US?
How does FYB206's development compare?
What are the terms of Formycon's bond?
How Phase III waiver impacts future pipeline?
FYB202 US revenue ramp-up drivers for Q4?
FYB203 launch: What are key IP resolution signs?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Formycon earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Formycon AG is a German biotechnology company specializing in the development of biosimilars, which are biologic medical products highly similar to approved reference drugs. The company's portfolio includes biosimilars for treatments in areas such as ophthalmology and immunology, targeting chronic diseases with a high demand for cost-effective therapies. Formycon is involved in all stages of biosimilar development, from research and production to clinical trials and regulatory approval, aiming to expand access to high-quality biologics in global markets.The company is headquartered in Planegg, Germany, and its shares are listed on the Frankfurt Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage